Revvity, Inc. (RVTY)
102.52
-0.74
(-0.72%)
USD |
NYSE |
Dec 04, 16:00
102.52
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 11.62B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -9.97% |
| Valuation | |
| PE Ratio | 51.27 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 4.328 |
| Price to Book Value | 1.576 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.07 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.4568 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 59.01% |
Profile
| Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. The firm operates through the following segments: Life Sciences and Diagnostics. The Life Sciences segment delivers innovative solutions to optimize workflows, boost productivity, and accelerate drug discovery and development. The Diagnostics segment provides instruments, reagents, assay platforms, and software to healthcare and research professionals, with a focus on reproductive health, immunodiagnostics, emerging market diagnostics, and applied genomics to enhance patient outcomes. Revvity was founded on April 19, 1937 and is headquartered in Waltham, MA. |
| URL | http://www.revvity.com |
| Investor Relations URL | https://ir.revvity.com/events-and-presentations/default.aspx |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Next Earnings Release | Jan. 26, 2026 (est.) |
| Last Earnings Release | Oct. 27, 2025 |
| Next Ex-Dividend Date | Jan. 16, 2026 |
| Last Ex-Dividend Date | Oct. 17, 2025 |
Ratings
Profile
| Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. The firm operates through the following segments: Life Sciences and Diagnostics. The Life Sciences segment delivers innovative solutions to optimize workflows, boost productivity, and accelerate drug discovery and development. The Diagnostics segment provides instruments, reagents, assay platforms, and software to healthcare and research professionals, with a focus on reproductive health, immunodiagnostics, emerging market diagnostics, and applied genomics to enhance patient outcomes. Revvity was founded on April 19, 1937 and is headquartered in Waltham, MA. |
| URL | http://www.revvity.com |
| Investor Relations URL | https://ir.revvity.com/events-and-presentations/default.aspx |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Next Earnings Release | Jan. 26, 2026 (est.) |
| Last Earnings Release | Oct. 27, 2025 |
| Next Ex-Dividend Date | Jan. 16, 2026 |
| Last Ex-Dividend Date | Oct. 17, 2025 |